Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a spermidine-based nutritional supplement increased the number of anagen phase hair follicles in healthy humans, suggesting potential benefits for hair loss conditions.

This study suggests that Eclipta prostrata may promote hair growth in mice and human dermal papilla cells through regulating FGF-7 and mTOR signaling.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

This study found that biglycan, a protein secreted by dermal papilla cells, plays a critical role in hair follicle cycle regulation and regeneration in mice by activating the Wnt/β-catenin signalling pathway, suggesting its potential as a treatment target for hair loss.

In this study, γ-ray irradiation of mice reduced hair follicle density and pigmentation, suggesting damage to stem cells and progenitors for keratinocytes and melanocytes.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This study reports that Plantago asiatica L. extract may promote hair growth by enhancing growth factor production and activating specific signaling pathways in hair follicle dermal papilla cells.

This study investigated the role of autophagy in human dermal papilla cells and found that inhibiting autophagy accelerates the catagen phase by reducing Wnt/β-catenin signaling. Furthermore, adding ginsenoside Re appears to restore autophagy, suggesting potential benefits for mitigating hair loss linked to autophagy inhibition.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study found that exosomes derived from bovine colostrum promoted hair growth in mice by activating the Wnt/β-catenin pathway, with effects similar to minoxidil but without adverse effects.

This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study found that CARI ONE, a herbal mixture, promotes hair growth in mice by inducing the transition from telogen to anagen phase and enhancing hair follicle development, compared to control and minoxidil treatments.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

In this study, the elimination of NG2+ hair follicle stem cells during the anagen phase was associated with an aggravated sensitization phase of allergic contact dermatitis, suggesting their immunosuppressive role.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that the Spanish version of the hair-specific Skindex-29 questionnaire effectively detected changes in health-related quality of life among women with female-pattern hair loss, and the scores were significantly correlated with the SF-12 survey results after treatment with a 5 alpha-reductase inhibitor.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This study found that FGF18 signaling helps protect hair follicles from radiation damage by maintaining the resting phase and supporting stem cell survival, potentially reducing radiation-induced hair loss.

This research reported that STAT5 activation in the dermal papilla plays a crucial role in triggering anagen entry during post-developmental hair follicle cycling.

This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.